sarcoma

[Oncogene] Investigators showed that oral administration of propranolol delayed tumor progression of MCA205 fibrosarcoma model and MC38 colon cancer model and increased the survival rate of tumor bearing mice.

[BioAtla, Inc. (PR Newswire, Inc.)] BioAtla, Inc. announced that it has entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy nivolumab.

[Aging] The authors evaluated the N6-methyladenosine (m6A) regulator expression patterns in patients with sarcoma based on known 23 m6A regulators. Different m6A regulator expression patterns were analyzed using gene set variation analysis and a single-sample gene set enrichment analysis algorithm.

[Molecular Therapy-Oncolytics] The authors analyzed the gene expression and outcome of 980 sarcoma patients from seven public datasets. The abundance of immune cells and the response to immunotherapy was calculated.

[Communications Biology] The authors discuss promising Matrigel-free methods for the generation and maintenance of organoids that use decellularized ECM, synthetic hydrogels, or gel-forming recombinant proteins.

[QSAM Biosciences, Inc.] QSAM Biosciences, Inc. announced the activation of its first clinical trial site and the initiation of enrollment of patients into its Phase I clinical trial evaluating CycloSam® for multiple types of bone cancer that either originated in or has metastasized to the bone.